UDON Therapy: A Promising Regimen for Esophageal Cancer
A phase II trial reveals that the UDON regimen (5-Fluorouracil, Docetaxel, and Nedaplatin) shows promising antitumor activity and good tolerability for patients battling advanced esophageal cancer, potentially providing a new treatment option with manageable side effects.